|
Vol. 9.27 – 22 July, 2020
|
|
|
|
|
|
The authors showed, using a mouse model of squamous cell carcinoma, that tumor-initiating cells played a crucial role in creating a niche microenvironment that was required for tumor progression and drug resistance.
[Science]
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
Researchers showed that the combination treatment of anti-PD1 and cisplatin enriched BMI1+ CSCs in head and neck squamous cell carcinoma (HNSCC) while inhibiting HNSCC growth.
[Cell Stem Cell]
|
|
|
|
|
Scientists showed that LEFTY1, a secreted inhibitor of NODAL/SMAD2 signaling, was produced by mammary progenitor cells and, concomitantly, suppressed SMAD2 and SMAD5 signaling to promote long-term proliferation of normal and malignant mammary epithelial cells.
[Cell Stem Cell]
|
|
|
|
|
Investigators describe the immunoreceptor tyrosine-based inhibition motif-containing Fc gamma receptor IIb for being critical in leukemic stem cell resistance and showed that targeting FcγRIIb downstream signaling, by using a Food and Drug Administration-approved BTK inhibitor, provided a successful therapeutic approach.
[Leukemia]
|
|
|
|
|
Scientists found that the expression of STAP-1 was aberrantly upregulated in chronic myeloid leukemia (CML) stem cells in patients’ bone marrow.
[Oncogene]
|
|
|
|
|
Knockdown of nerve growth factor receptor (NGFR) markedly reduced the size and number of spheroid formation of melanoma cells, which could be rescued by ectopically expressed NGFR.
[Cell Death & Disease]
|
|
|
|
|
Investigators present a method for label-free detection of circulating tumor cells from patient blood samples, by taking advantage of data analysis of bright field microscopy images.
[Scientific Reports]
|
|
|
|
|
Scientists performed studies of viability, type of cell death, cancer stem cell percent and glycosphingolipid expression on CSC and non-CSC after treatment of MDA-MB-231 and MDA-MB-453 triple-negative breast cancer cells with a newly developed thienopyridine anticancer compound.
[Scientific Reports]
|
|
|
|
|
|
The authors summarize the latest advances in the understanding of PI3K/AKT/SOX2-driven stemness and its intertwined relations to p53-signaling in DNA damage response under conditions of pluripotency, reprogramming, and transformation.
[International Journal of Molecular Sciences]
|
|
|
|
|
|
Karolinska Development AB announces that its portfolio company Aprea Therapeutics has decided to expand the enrollment of patients in its Phase I clinical trial evaluating eprenetapopt in TP53 mutant acute myeloid leukemia.
[Karolinska Development AB]
|
|
|
|
|
Aprea Therapeutics, Inc. announced the expansion of patient enrollment in its Phase I clinical trial evaluating eprenetapopt in TP53 mutant AML.
[Aprea Therapeutics, Inc.]
|
|
|
|
|
A historic €1.8-trillion (US$2.1-trillion) budget deal reached by European Union (EU) leaders to fund its next seven years — and its recovery from the coronavirus pandemic — has left scientists and research advocates disappointed.
[Nature News]
|
|
|
|
|
|
August 27 – August 29
Virtual
|
|
|
|
|
|
|
Cincinnati Children’s Hospital Medical Center – Cincinnati, Ohio, United States
|
|
|
|
|
West Virginia University – Morgantown, West Virginia, United States
|
|
|
|
|
Lund University – Lund, Sweden
|
|
|
|
|
Massachusetts General Hospital – Charlestown, Massachusetts, United States
|
|
|
|
|
Shanghai Jiao Tong University – Shanghai, China
|
|
|
|
|